AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10456339 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Skin Equivalent (LSE)
Number of subjects: 20
Study 10456339 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 20
Study 10456339 — intervention group
Group type: COMPARATOR
Intervention: PUF (Polyurethane Film) occlusive dressing
Number of subjects: 20
Study 10456339 — intervention group
Group type: EXPERIMENTAL
Intervention: LSE
Number of subjects: 20
Study 10456339 — intervention group
Group type: COMPARATOR
Intervention: PUF
Number of subjects: 20
Study 7880791 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fusidic acid gel (Fucithalmic)
Number of subjects: 0
Study 7880791 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxytetracycline
Number of subjects: 0
Study 7880791 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fusidic acid gel and oxytetracycline
Number of subjects: 0
Study 2245455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (20 mg twice a day)
Number of subjects: 30
Study 2245455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 386974 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg propylthiouracil every two hours (group A)
Number of subjects: 24
Study 386974 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg, 100 mg, and 150 mg propylthiouracil at 8 hour intervals (group B)
Number of subjects: 24
Study 31171876 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab + cobimetinib + vemurafenib
Number of subjects: 0
Study 31171876 — intervention group
Group type: COMPARATOR
Intervention: Cobimetinib + vemurafenib (run-in period)
Number of subjects: 0
Study 31171876 — intervention group
Group type: COMPARATOR
Intervention: Vemurafenib (run-in period)
Number of subjects: 0
Study 28794054 — intervention group
Group type: EXPERIMENTAL
Intervention: Random survival forests technique
Number of subjects: 6814
Study 25724571 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverse interventions including improved communication, changes in workflow, and targeted quality improvement (QI) projects
Number of subjects: 166
Study 25724571 — intervention group
Group type: EXPERIMENTAL
Intervention: Workflow interventions
Number of subjects: 166
Study 25724571 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted QI projects
Number of subjects: 166
Study 25724571 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions in communication or workflow
Number of subjects: 166
Study 23514874 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural anesthesia with ropivacaine, fentanyl, and epinephrine
Number of subjects: 85
Study 23514874 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with sevoflurane and fentanyl, and systemically administered opioids
Number of subjects: 85
Study 21199979 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 410
Study 21199979 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Blocks (BB)
Number of subjects: 410
Study 21199979 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 410
Study 19144532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (1000 mg/day by intravenous infusion on the day of operation and on the first 3 postoperative days)
Number of subjects: 140
Study 19144532 — intervention group
Group type: COMPARATOR
Intervention: Fluid therapy only without ambroxol
Number of subjects: 140
Study 16670830 — intervention group
Group type: EXPERIMENTAL
Intervention: Action potential simulation (APS)
Number of subjects: 10
Study 16670830 — intervention group
Group type: COMPARATOR
Intervention: Placebo APS
Number of subjects: 10
Study 16004778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 40
Study 16004778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intensive insulin therapy)
Number of subjects: 40
Study 11695212 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Plus Whitening Toothpaste
Number of subjects: 93
Study 11695212 — intervention group
Group type: COMPARATOR
Intervention: Colgate Total Toothpaste
Number of subjects: 93
Study 9790365 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial membrane sweeping every 3 days
Number of subjects: 65
Study 9790365 — intervention group
Group type: COMPARATOR
Intervention: Gentle examinations every 3 days (Control)
Number of subjects: 65
Study 8085180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month, 6-month, and 1-year prevalence rates for mental disorders
Number of subjects: 0
Study 8085180 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abuse
Number of subjects: 0
Study 8085180 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dependence
Number of subjects: 0
Study 8085180 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive disorders
Number of subjects: 0
Study 8085180 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 0
Study 2681508 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine 12 g b.i.d.
Number of subjects: 20
Study 2681508 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg q.p.m.
Number of subjects: 20
Study 2681508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Simvastatin + Cholestyramine)
Number of subjects: 20
Study 2681508 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin monotherapy after 52 weeks
Number of subjects: 20
Study 2681508 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 20
Study 1251131 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 441
Study 1251131 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxonomic classification
Number of subjects: 441
Study 1251131 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical classifications based on sex, alcoholism, and compensation
Number of subjects: 441
Study 1251131 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 441
Study 31937344 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 146
Study 31937344 — intervention group
Group type: COMPARATOR
Intervention: Placebo-surgery
Number of subjects: 146
Study 30195601 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified nerve-sparing thoracotomy
Number of subjects: 90
Study 30195601 — intervention group
Group type: COMPARATOR
Intervention: Standard posterolateral thoracotomy (control)
Number of subjects: 90
Study 28410617 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (2 g/day for 3 months)
Number of subjects: 74
Study 28410617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 26118567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented TKA
Number of subjects: 100
Study 26118567 — intervention group
Group type: COMPARATOR
Intervention: Cementless TKA
Number of subjects: 100
Study 24069844 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD) applied after Scaling and Root Planing (SRP)
Number of subjects: 20
Study 24069844 — intervention group
Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 20
Study 24069844 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP) combined with EMD
Number of subjects: 20
Study 24069844 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical therapy with EMD
Number of subjects: 20
Study 21739692 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut-embedding combined western medicine (ACCWM)
Number of subjects: 52
Study 21739692 — intervention group
Group type: COMPARATOR
Intervention: Simple western medicine (WM)
Number of subjects: 52
Study 19699861 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-cTnI assay
Number of subjects: 100
Study 19699861 — intervention group
Group type: COMPARATOR
Intervention: current-generation cTnI
Number of subjects: 100
Study 16714961 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief focal ultrasound followed by a 5-minute application of a 4% lidocaine topical anesthetic
Number of subjects: 77
Study 16714961 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 77
Study 15020185 — intervention group
Group type: COMPARATOR
Intervention: bupropion
Number of subjects: 600
Study 15020185 — intervention group
Group type: EXPERIMENTAL
Intervention: not smoking menthol cigarettes
Number of subjects: 600
Study 15020185 — intervention group
Group type: EXPERIMENTAL
Intervention: smoking after 30 min of waking
Number of subjects: 600
Study 15020185 — intervention group
Group type: EXPERIMENTAL
Intervention: older age
Number of subjects: 600
Study 15020185 — intervention group
Group type: EXPERIMENTAL
Intervention: smoking fewer cigarettes per day
Number of subjects: 600
Study 15020185 — intervention group
Group type: EXPERIMENTAL
Intervention: lower cotinine levels
Number of subjects: 600
Study 11323371 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (10 mg)
Number of subjects: 18
Study 11323371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9293935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intermittent sequential compression (ISC)
Number of subjects: 50
Study 9293935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ISC)
Number of subjects: 50
Study 8123895 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 MU IFN
Number of subjects: 81
Study 8123895 — intervention group
Group type: COMPARATOR
Intervention: 3 MU IFN
Number of subjects: 81
Study 3621341 — intervention group
Group type: EXPERIMENTAL
Intervention: Superflow (5F) catheter
Number of subjects: 34
Study 3621341 — intervention group
Group type: COMPARATOR
Intervention: 8F catheter
Number of subjects: 34
Study 31128267 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CTP)
Number of subjects: 0
Study 31128267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30302147 — intervention group
Group type: EXPERIMENTAL
Intervention: Subxiphoid port
Number of subjects: 182
Study 30302147 — intervention group
Group type: COMPARATOR
Intervention: Umbilical port
Number of subjects: 182
Study 30302147 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 182
Study 27199121 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol (5-20 mg/day)
Number of subjects: 25
Study 27199121 — intervention group
Group type: COMPARATOR
Intervention: metoprolol succinate (100-300 mg/day)
Number of subjects: 25
Study 25701829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg, 2 times a day (n = 27)
Number of subjects: 54
Study 23412897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 15 liters/min
Number of subjects: 10
Study 23412897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 30 liters/min
Number of subjects: 10
Study 23412897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 45 liters/min
Number of subjects: 10
Study 23412897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) during sleep at 15 liters/min
Number of subjects: 10
Study 23412897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) during sleep at 30 liters/min
Number of subjects: 10
Study 23412897 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 10
Study 19451137 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA combination therapy (step-down prednisolone, methotrexate, and sulfasalazine)
Number of subjects: 155
Study 19451137 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ) monotherapy
Number of subjects: 155
Study 18193385 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (800 mg on day 1, then 400 mg/day) + piperacillin/tazobactam + gentamicin
Number of subjects: 100
Study 18193385 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (2 g/day) + meropenem + levofloxacin
Number of subjects: 100
Study 18193385 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 100
Study 18193385 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 100
Study 18193385 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin with amphotericin B
Number of subjects: 100
Study 18193385 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin with amphotericin B
Number of subjects: 100
Study 17106142 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (4 mg, most frequent dose)
Number of subjects: 157
Study 17106142 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 157
Study 17106142 — intervention group
Group type: COMPARATOR
Intervention: ACEI (lisinopril, enalapril, trandolapril)
Number of subjects: 157
Study 12612168 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplements with supplemental calcium
Number of subjects: 0
Study 12612168 — intervention group
Group type: EXPERIMENTAL
Intervention: Total protein intake with supplemental calcium citrate malate and vitamin D
Number of subjects: 0
Study 12612168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11778479 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified two ways connection
Number of subjects: 7
Study 11778479 — intervention group
Group type: COMPARATOR
Intervention: Conventional set-up
Number of subjects: 7
Study 8632120 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate 10 mg
Number of subjects: 11
Study 8632120 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate 25 mg
Number of subjects: 11
Study 8632120 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate 50 mg
Number of subjects: 11
Study 8632120 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate 100 mg
Number of subjects: 11
Study 1600852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (8 mg per day)
Number of subjects: 18
Study 1600852 — intervention group
Group type: COMPARATOR
Intervention: Captopril (75 mg per day)
Number of subjects: 18
Study 1600852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine and Captopril
Number of subjects: 18
Study 2866789 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 1% eyedrops
Number of subjects: 6
Study 2866789 — intervention group
Group type: EXPERIMENTAL
Intervention: L-714,465 1% eyedrops
Number of subjects: 6
Study 2866789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (methyl-cellulose)
Number of subjects: 6
Study 29797713 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cm syringes
Number of subjects: 30
Study 29797713 — intervention group
Group type: COMPARATOR
Intervention: 2 cm cups
Number of subjects: 30
Study 27281645 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer in strategic workplace locations and personal use
Number of subjects: 0
Study 27281645 — intervention group
Group type: COMPARATOR
Intervention: Brief hand hygiene education
Number of subjects: 0
Study 24520097 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 risk-of-recurrence (ROR) score
Number of subjects: 1246
Study 24520097 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 ROR-based risk groups
Number of subjects: 1246
Study 24520097 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ROR-based risk group
Number of subjects: 1246
Study 24520097 — intervention group
Group type: EXPERIMENTAL
Intervention: High ROR-based risk group
Number of subjects: 1246
Study 22456954 — intervention group
Group type: EXPERIMENTAL
Intervention: Date palm immunotherapy (IT) for 15 months
Number of subjects: 30
Study 19860762 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 525
Study 19860762 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 525
Study 19860762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study 18565853 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine plus low-dose cytarabine
Number of subjects: 70
Study 18565853 — intervention group
Group type: COMPARATOR
Intervention: Clofarabine alone
Number of subjects: 70
Study 15823640 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 3140
Study 15823640 — intervention group
Group type: EXPERIMENTAL
Intervention: switching to rosuvastatin 10 mg from atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 40 mg
Number of subjects: 3140
Study 15823640 — intervention group
Group type: EXPERIMENTAL
Intervention: switching to rosuvastatin 20 mg from atorvastatin 20 mg
Number of subjects: 3140
Study 15823640 — intervention group
Group type: EXPERIMENTAL
Intervention: switching to rosuvastatin 10 mg from atorvastatin 20 mg
Number of subjects: 3140
Study 12874270 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (etoposide plus cisplatin) plus daily radiation therapy (RT)
Number of subjects: 246
Study 12874270 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (etoposide plus cisplatin) plus split-course radiation therapy (RT) bid
Number of subjects: 246
Study 10381769 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg MDMA
Number of subjects: 8
Study 10381769 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg MDMA
Number of subjects: 8
Study 10381769 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg amphetamine
Number of subjects: 8
Study 10381769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9345413 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric monoclonal anti-CD4 antibodies
Number of subjects: 0
Study 1879990 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin (5 mg/kg intramuscularly)
Number of subjects: 96
Study 1879990 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (15 mg/kg intramuscularly)
Number of subjects: 96
Study 1879990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (3 g per os)
Number of subjects: 96
Study 6177264 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch 200/0.5
Number of subjects: 20
Study 6177264 — intervention group
Group type: COMPARATOR
Intervention: 10% dextran 40
Number of subjects: 20
Study 31830982 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive use
Number of subjects: 1460
Study 31830982 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary education
Number of subjects: 1460
Study 31830982 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a sexual partner within 5 years of their age
Number of subjects: 1460
Study 31830982 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual debut at age 15 years and older
Number of subjects: 1460
Study 31830982 — intervention group
Group type: EXPERIMENTAL
Intervention: Other race groups (White, Coloured, Indians/Asians)
Number of subjects: 1460
Study 31830982 — intervention group
Group type: EXPERIMENTAL
Intervention: Being married
Number of subjects: 1460
Study 31830982 — intervention group
Group type: EXPERIMENTAL
Intervention: Never given birth
Number of subjects: 1460
Study 31830982 — intervention group
Group type: EXPERIMENTAL
Intervention: Coming from rural informal settlements
Number of subjects: 1460
Study 31830982 — intervention group
Group type: EXPERIMENTAL
Intervention: Coming from rural formal settlements
Number of subjects: 1460
Study 28657871 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (10 mg/day for 3 weeks, then 20 mg/day)
Number of subjects: 245
Study 28657871 — intervention group
Group type: COMPARATOR
Intervention: tDCS (30-minute, 2-mA sessions for 15 weekdays, followed by 7 weekly treatments)
Number of subjects: 245
Study 28657871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral placebo)
Number of subjects: 245
Study 25819170 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram injection
Number of subjects: 45
Study 25819170 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 45
Study 24047756 — intervention group
Group type: EXPERIMENTAL
Intervention: A-tDCS (1 mA, 10 min)
Number of subjects: 24
Study 24047756 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (S-tDCS: 1 mA, 25 sec)
Number of subjects: 24
Study 21357794 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical binge eaters (6% of participants)
Number of subjects: 678
Study 21357794 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical binge eaters (20% of participants)
Number of subjects: 678
Study 21357794 — intervention group
Group type: COMPARATOR
Intervention: Nonovereaters and overeaters (comparison group)
Number of subjects: 678
Study 20032908 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections with static night splint
Number of subjects: 20
Study 20032908 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A injections without static night splint
Number of subjects: 20
Study 18396651 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF-100 regimen (epirubicin 100 mg/m2, dl per 21 days for 6 cycles, n =48)
Number of subjects: 98
Study 18396651 — intervention group
Group type: COMPARATOR
Intervention: CEF-60 regimen (epirubicin 60 mg/m2, dl per 21 days for 6 cycles, n = 50)
Number of subjects: 98
Study 15274695 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-pulse erbium:YAG laser (one pass over the entire face, two to three passes over perioral and periorbital regions)
Number of subjects: 20
Study 15274695 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-pulse erbium:YAG laser (two and three passes)
Number of subjects: 20
Study 15274695 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-pulse erbium:YAG laser
Number of subjects: 20
Study 15297048 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18 L1 VLP vaccine
Number of subjects: 40
Study 15297048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10524837 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg/day
Number of subjects: 195
Study 10524837 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 50 mg/day
Number of subjects: 195
Study 10524837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 8545754 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief scale (Outlook score and Support score)
Number of subjects: 40
Study 8545754 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief scale (Support score)
Number of subjects: 40
Study 8545754 — intervention group
Group type: COMPARATOR
Intervention: HADS (Hospital Anxiety and Depression Scale)
Number of subjects: 40